Brief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
08/07/2026 15:44
BRIEF-Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc July 8 (Reuters) - Maia Biotechnology Inc MAIA.A:
MAIA BIOTECHNOLOGY REPORTS STRONG INITIAL EFFICACY DATA IN THIRD-LINE NON-SMALL CELL LUNG CANCER FROM PHASE 2 THIO-101 PART C EXPANSION TRIAL
MAIA BIOTECHNOLOGY - ATEGANOSINE PLUS CEMIPLIMAB SHOWS ACCEPTABLE SAFETY PROFILE IN HEAVILY PRE-TREATED PATIENTS
MAIA BIOTECHNOLOGY - THIO-101 PART C SHOWS 90.5% DISEASE CONTROL RATE IN 3L NSCLC
MAIA BIOTECHNOLOGY - ATEGANOSINE PLUS CEMIPLIMAB OUTPERFORMS STANDARD CHEMOTHERAPY DCR IN 3L NSCLC
Source text: ID:nGNX49klM5
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale